Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults

Nelson, Harold S.; Nolte, Hendrik; Creticos, Peter S.; Maloney, Jennifer; Wu, Jiangming; Bernstein, David I.

doi:10.1016/j.jaci.2010.11.035

Cited by 193 publications

(196 citation statements)

References 36 publications

(48 reference statements)

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…But since then five additional RCTs have been published, all conducted in North America. [107,108,[125][126][127].…”

Section: Sublingual Immunotherapymentioning

confidence: 99%

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Lorenzo¹,

Leto-Barone²,

Piana³

et al. 2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

The lack of medication for allergy symptoms at the end of the last millennium has been the promoter of the idea of treating allergies as if you were treating an infectious disease, by vaccination prophylaxis. Two forms of AIT 1) subcutaneous immunotherapy (SCIT) and 2) sublingual immunotherapy (SLIT) are used in the world. Considerable interest has emerged in SLIT both scientifically and especially financially. SLIT is not a new treatment modality. First description dates back to 1900 when H. Curtis. It was relatively widely used until the late 1970's mainly in US by homeopathic therapists.A number of case series describing experience with the oral route were published during the 1920s and 1930s, but it seems to have been perceived not as efficacious nor as well tolerated as subcutaneous immunotherapy. The companies producing allergen immunotherapy have an alliance with important opinion leaders on both shores of the Atlantic.If SLIT did not work for 40 years, why should it work for respiratory allergic diseases today? This question is the mother of all questions in the field of respiratory allergic diseases. The purpose of this chapter is to provide past and current information about immunotherapy, and discuss controversies over efficacy and safety, and dosing considerations for SLIT to grass.

show abstract

“…But since then five additional RCTs have been published, all conducted in North America. [107,108,[125][126][127].…”

Section: Sublingual Immunotherapymentioning

confidence: 99%

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Lorenzo¹,

Leto-Barone²,

Piana³

et al. 2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

show abstract

“…The RQLQ has been used in many well-powered clinical trials as a secondary outcome both for subcutaneous [38,39] and sublingual immunotherapy [40][41][42][43] in adults and children [44]. These studies have shown that immunotherapy improves HRQoL in allergic rhinoconjunctivitis patients.…”

Section: ) Generic Questionnairesmentioning

confidence: 99%

Health-Related Quality of Life and Rhinitis Control Measures in Allergic Rhinitis

Makatsori

Koulias

Calderón

2014

Curr Treat Options Allergy

View full text Add to dashboard Cite

“…The standardised sublingual grass allergy immunotherapy tablet (SQ Ò grass SLIT tablet) has been developed for sublingual application in patients with grass pollen-induced rhinoconjunctivitis, and has been investigated in more than 5700 patients in controlled clinical trials in Europe and North America [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. It has been approved Europe-wide and was launched in Germany in November 2006.…”

Section: Introductionmentioning

confidence: 99%

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

Schwab¹,

Wolf

Schnitker

et al. 2018

Pulm Ther

View full text Add to dashboard Cite

Introduction: Intra-seasonal start of treatment with the SQ Ò grass sublingual immunotherapy (SLIT) tablet (GRAZAX Ò , ALK, Denmark) has been previously demonstrated to be well-tolerated. The objective of our study was to investigate the tolerability of intra-seasonal start of treatment comparing patients treated by allergists and general practitioners experienced in treatment of allergy (GPs). Methods: In a non-interventional, open-label, observational study, data on intra-seasonal start

show abstract

Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults

Cited by 193 publications

References 36 publications

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Health-Related Quality of Life and Rhinitis Control Measures in Allergic Rhinitis

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

Contact Info

Product

Resources

About